Your JM Support Community
Cure JM is powered by a community of families who have successfully navigated the JM journey and are here to help you do the same.
Get connected with a network of support, encouragement, and resources.
![](https://www.curejm.org/wp-content/uploads/Join-curejm-2.gif)
![Two happy children: one with "Hope" chalkboard sign and the other holding a red balloon.](https://www.curejm.org/wp-content/uploads/cure-jm-welcome-1000x939.jpg)
Cure JM is the global leader in juvenile myositis (JM) research. We are paving the way to better treatments for JM while improving the lives of families affected by the disease.
About
Juvenile Myositis
Juvenile myositis involves a run-away immune response where the body’s immune system attacks its own cells and tissues. With proper treatment and care, children can go on to live their best lives.
![](https://www.curejm.org/wp-content/uploads/Screen-Shot-2022-07-28-at-6.24.20-PM.jpg)
We are honored to share our new short film, “Our Mission, Our Impact,” highlighting the key aspects of our mission, working together to make life-changing impacts for the patients and families we serve. Please join us in celebrating the impacts of this progress by making a gift and sharing this video.
Resources
![Getting the Diagnosis. Megan Curran, MD](https://www.curejm.org/wp-content/uploads/getting-the-diagnosis-1500x954-2-1000x636.jpg)
Getting the Diagnosis
It often takes a bit of time for children with juvenile myositis (JM) to get a proper diagnosis. This is due to the fact that
![Doctor with parent and juvenile myositis patient.](https://www.curejm.org/wp-content/uploads/Dr-K-Caroline-2-2-1.jpeg)
Treatment Plans for Juvenile Myositis
A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms
![](https://www.curejm.org/wp-content/uploads/fundraising-2-1000x563.gif)
DIY Fundraising
Fundraising doesn’t have to be a daunting task…We’d like to invite our families to join us in putting the “Fun” in fundraising.
Get Involved
Discover the many ways you can support and connect with Cure JM.
![](https://www.curejm.org/wp-content/uploads/Get-involved-cc.jpg)
We invite you to get involved with Cure JM. We hope you’ll join us in helping make our mission a success.
![Lemonade Logo with call to action](https://www.curejm.org/wp-content/uploads/Lemonade-Graphic-1136X639.png)
As parents, patients, and supporting family members, we understand that a juvenile myositis diagnosis can be one of life’s “lemons.” We’ve decided to turn our lemons into sweet lemonade in support of our mission of finding better treatments and a cure for JM.
Funds raised through “Lemons to Lemonade for Kids” will be directly invested in cutting-edge research projects and expanding access to best-practice clinical care.
Finding a Cure and Better Treatments for Juvenile Myositis
Cure JM is accelerating juvenile myositis research at an unprecedented pace. We are pursuing promising new treatments, funding clinical trials, and improving care for patients.
Research
New Treatments
Trials
Care Network
Current Research Updates
The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.
Cabaletta Bio Presents Promising Early Data for CAR-T in Myositis
Exciting news from the European Congress of Rheumatology (EULAR) 2024 last month in Vienna, Austria! Cure JM partner Cabaletta Bio, presented encouraging results from their CAR-T cell therapy, CABA-201, in treating myositis.
Initial data from the first two patients dosed with CABA-201 showed positive signs in terms of safety, clinical response, and biological markers. Cabaletta believes this data validates the potential of CABA-201 to “reset the immune system” in patients with myositis and other autoimmune diseases.
ProDerm Study Reports a Milestone in Managing Adult Myositis
Recently, the Progress in Dermatomyositis ProDERM study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s favorable results, adult myositis patients have new hope with the approval of Octagam® 10%.
A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients.
![Photo of a young couple](https://www.curejm.org/wp-content/uploads/leah-testimonial-e1664753268159.jpg)
“Cure JM has provided us so much support and connected us to so many families that were experiencing or had experienced the exact same thing. That sense of community helped us get through the ups and downs.”
Join Cure JM
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
![Cure JM supports families, patients, and the juvenile myositis research community.](https://www.curejm.org/wp-content/uploads/join-cure-jm-1000x679.png)